Clinical trial
Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in…
NCT00274820 · Case Comprehensive Cancer Center, Other · Completed
Key facts
| NCT number | NCT00274820 |
|---|---|
| Title | Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Myelofibrosis/Myeloproliferative Disorder |
| Official title | A Phase II Trial of Combination Therapy With Thalidomide, Arsenic Trioxide, Dexamethasone, and Ascorbic Acid (TADA) in Patients With Chronic Idiopathic Myelofibrosis or Overlap Myelodysplastic/Myeloproliferative Disorders |
| Lead sponsor | Case Comprehensive Cancer Center, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Chronic Myeloproliferative Disorders, Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases |
| Intervention type | Dietary Supplement, Drug |
| Interventions | ascorbic acid, arsenic trioxide, dexamethasone, thalidomide |
| Enrollment | 15 |
| Start date | Oct 1, 2005 |
| Primary completion | Sep 1, 2007 |
| Completion | Oct 1, 2007 |
| First posted | Jan 11, 2006 |
| Last update posted | Jul 27, 2020 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: